Business Context and Reporting Period
This Form 8-K filing by GRI Bio, Inc. (Nasdaq: GRI) reports a material change in executive compensation effective June 17, 2024. The report details an amendment to the employment agreement of Albert Agro, Ph.D., the Company's Chief Medical Officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
- Compensation Reduction: Dr. Agro's annual base salary was reduced from $325,000 to $100,000.
- Bonus Elimination: Dr. Agro is no longer eligible for an annual cash performance bonus.
- Severance Removal: Provisions for severance payments upon termination without cause or resignation for good reason were removed.
- Work Commitment: Dr. Agro is now required to work at least 70 hours per month for the Company, with the balance of time available for other consulting or employment.
- Termination Terms: Employment may now be terminated by either party with 30 days' prior written notice, with payment limited to earned salary and unreimbursed expenses.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of general risks and contingencies beyond the specific terms of the employment amendment.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 to the Employment Agreement (Exhibit 10.1) for any additional clauses not summarized in the 8-K.
- Assess the impact of the reduced CMO workload (70 hours/month) on the Company's clinical development timelines.
- Review recent cash burn rates to understand the necessity of this cost-cutting measure.
- Check for any concurrent filings regarding other executive departures or compensation changes.